Rock Point Advisors’s Boston Scientific BSX Stock Holding History

Rock Point Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,163	Closed	-$2.21M	–	120
2025 Q4	$2.21M	Buy	+23,163	New	+$2.27M	0.55%	49

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rock Point Advisors's BSX Position: Q1 2026 in Review

Rock Point Advisors sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 23,163 shares — an estimated $2.21M sold.

Rock Point Advisors first reported a position in BSX in Q4 2025 and held it in 1 quarter. The position peaked at $2.21M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Rock Point Advisors reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Rock Point Advisors sold 23,163 Boston Scientific shares in Q1 2026, an estimated $2.21M.
Rock Point Advisors first reported a position in Boston Scientific in Q4 2025 and held it in 1 quarter.
Rock Point Advisors's Boston Scientific position peaked at $2.21M in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Rock Point Advisors's 13F filing for Q1 2026, filed 14 May 2026.